Last reviewed · How we verify
NCT03738683: PICTAR
Pharmacokinetics of Piperacillin and Tazobactam in Critically Ill Patients
trial testing Piperacillin/tazobactam in Bacterial Infections in 40 participants. Completed in 1 October 2019.
1 September 2019
Quick facts
| Lead sponsor | Radboud University Medical Center |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 1 February 2019 |
| Primary completion | 1 September 2019 |
| Estimated completion | 1 October 2019 |
| Sites | 2 locations across Netherlands |
Drugs / interventions tested
- Piperacillin/tazobactam
Conditions studied
- Bacterial Infections — all drugs for Bacterial Infections →
Sponsor
Radboud University Medical Center
Who can join
18 and older, any sex, with Bacterial Infections. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Optimal understanding of piperacillin-tazobactam pharmacokinetics in critically ill patients is lacking resulting in large variation of achieved exposure and possible inadequate therapy. The investigators hypothesize that drug dosing based on CKD-EPIcr-cys provides a useful method to individualize and optimize therapy for piperacillin-tazobactam and eventually improve outcome. In a multi-centre, observational, open-label study the investigators aim to define PK of free drug concentrations of both piperacillin and tazobactam in ICU patients and define a PK model for estimation of renal function that most accurately predicts piperacillin and tazobactam clearance.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
An Integral Pharmacokinetic Analysis of Piperacillin and Tazobactam in Plasma and Urine in Critically Ill Patients.
Wallenburg E, Ter Heine R, Schouten JA, Raaijmakers J, et al · · 2022 · cited 13× · PMID 35377133 · DOI 10.1007/s40262-022-01113-6 -
Small-molecule inhibitors of bacterial-producing metallo-β-lactamases: insights into their resistance mechanisms and biochemical analyses of their activities.
Ayipo YO, Chong CF, Mordi MN. · · 2023 · cited 4× · PMID 37360393 · DOI 10.1039/d3md00036b
Verify or expand the search:
- PubMed search for NCT03738683
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Piperacillin/tazobactam
Trials testing the same drug.
- NCT06422533 — Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological Patients · NA · recruiting
- NCT05981079 — Model-based Dose Versus Empirical Dose of Piperacillin/Tazobactam in Preterm Neonates With Late-onset Sepsis. · Phase 4 · unknown
- NCT04394182 — Ultra Low Doses of Therapy With Radiation Applicated to COVID-19 · NA · suspended
- NCT03671967 — PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enter · Phase 4 · recruiting
- NCT03687255 — Safety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract Infections · Phase 3 · completed
Other recruiting trials for Bacterial Infections
Currently open trials in the same condition.
- NCT07017777 — A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infant · Phase 3 · recruiting
- NCT07104162 — A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal I · Phase 1 · recruiting
- NCT07207291 — Phase I Study of Single/Multiple Ascending Doses of JKN2501 for Injection in Chinese Healthy Volunteers · Phase 1 · recruiting
- NCT07056881 — Monotherapy vs Combination Therapy for Bone Infections Caused by Pseudomonas Aeruginosa · recruiting
- NCT06592586 — A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant Women · Phase 2, PHASE3 · active not recruiting
Other Radboud University Medical Center trials
Trials by the same sponsor.
- NCT07485569 — Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial · Phase 1 · not yet recruiting
- NCT07514325 — MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer · NA · not yet recruiting
- NCT07530263 — Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA) · Phase 1 · not yet recruiting
- NCT07532577 — Intranasal Insulin to Prevent Intensive Care Unit Delirium · Phase 2, PHASE3 · not yet recruiting
- NCT07504172 — Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03738683 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Radboud University Medical Center
- Last refreshed: 21 November 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03738683.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing